KDIGO 2022 CLINICAL PRACTICE GUIDELINE FOR DIABETES MANAGEMENT IN CHRONIC KIDNEY DISEASE

被引：653

作者：

de Boer, Ian H. ^{[1
,2
]}

Rossing, Peter ^{[3
,4
,5
,6
]}

Caramori, M. Luiza ^{[7
,8
,9
,10
,11
]}

Chan, Juliana C. N. ^{[12
,13
]}

Heerspink, Hiddo J. L. ^{[14
,15
,16
,17
]}

Hurst, Clint ^{[18
]}

Khunti, Kamlesh ^{[19
,20
,21
,22
,23
,24
,25
]}

Liew, Adrian ^{[26
,27
,28
,29
,30
,31
,32
,33
,34
]}

Michos, Erin D. ^{[35
,36
,37
,38
,39
,40
,41
,42
,43
]}

Navaneethan, Sankar D. ^{[44
,45
,46
,47
]}

Olowu, Wasiu A. ^{[48
,49
]}

Sadusky, Tami ^{[50
,51
,52
,53
,54
,55
]}

Tandon, Nikhil ^{[56
,57
,58
,59
,60
,61
,62
,63
]}

Tuttle, Katherine R. ^{[64
,65
,66
,67
,68
,69
,70
,71
,72
,73
,74
]}

Wanner, Christoph ^{[75
,76
,77
,78
,79
]}

Wilkens, Katy G. ^{[80
,81
,82
]}

Zoungas, Sophia ^{[83
,84
,85
,86
,87
,88
]}

Jadoul, Michel ^{[89
,90
,91
,92
]}

Winkelmayer, Wolfgang C. ^{[92
,93
,94
,95
,96
,97
,98
,99
]}

Tonelli, Marcello A. ^{[100
,101
,102
,103
,104
,105
,106
]}

Craig, Jonathan C. ^{[107
,108
,109
,110
,111
,112
,113
,114
]}

Strippoli, Giovanni F. M. ^{[115
,116
]}

Tunnicliffe, David J. ^{[117
,118
,119
]}

Higgins, Gail Y. ^{[120
,121
,122
,123
]}

Natale, Patrizia ^{[124
,125
,126
]}

Cooper, Tess E. ^{[127
,128
]}

Willis, Narelle S. ^{[129
,130
]}

机构：

[1] Univ Washington, Epidemiol, Seattle, WA 98195 USA

[2] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA

[3] Steno Diabet Ctr Res Team, Copenhagen, Denmark

[4] Univ Copenhagen, Diabet Angiopathy, Copenhagen, Denmark

[5] European Diabet Nephropathy Study Grp, Copenhagen, Denmark

[6] Danish Natl Diabet Registry, Copenhagen, Denmark

[7] Univ Minnesota, Minneapolis, MN USA

[8] Univ Minnesota, Med Ctr, Joint Commiss Accredited Inpatient Diabet Serv, Minneapolis, MN 55455 USA

[9] NIH R01 Grant Study Protect Factors Diabet Kidney, Copenhagen, Denmark

[10] NKF Kidney Dis Outcomes Qual Initiat KDOQI Work G, Copenhagen, Denmark

[11] Diabet Nephropathy Subcomm ADA Sci Sess, Copenhagen, Denmark

[12] Chinese Univ Hong Kong, Med & Therapeut, Hong Kong, Peoples R China

[13] Chinese Univ Hong Kong, Hong Kong Inst Diabet & Obes, Hong Kong, Peoples R China

[14] Univ Med Ctr Groningen, Clin Trials & Personalized Med, Groningen, Netherlands

[15] Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands

[16] Univ New South Wales, Sydney, NSW, Australia

[17] George Inst Global Hlth, Sydney, NSW, Australia

[18] US Army, Washington, DC 20310 USA

[19] Univ Leicester, Primary Care Diabet & Vasc Med, Leicester, Leics, England

[20] UK Natl Inst Hlth Res NIHR Appl Res Collaborat AR, Leicester, Leics, England

[21] Ctr Ethn Hlth Res, Leicester, Leics, England

[22] Real World Evidence Unit, Leicester, Leics, England

[23] UK Govt Sci Advisory Grp Emergencies SAGE, Leicester, Leics, England

[24] SAGE Ethn Subpanel, Leicester, Leics, England

[25] Univ Melbourne, Dept Gen Practice, Melbourne, Vic, Australia

[26] Mt Elizabeth Novena Hosp, Kidney & Transplant Practice, Singapore, Singapore

[27] ISPD, Singapore, Singapore

[28] ISN, Execut Comm & Council, Singapore, Singapore

[29] ISN Oceania Southeast Asia Reg Board, Singapore, Singapore

[30] ISN End Stage Kidney Failure Strategy Dialysis Su, Singapore, Singapore

[31] ISN Renal Disaster Preparedness Working Grp, Singapore, Singapore

[32] ISN Dialysis Working Grp, Singapore, Singapore

[33] ISN Continuing Med Educ CME Comm, Singapore, Singapore

[34] Asia Pacific Soc Nephrol APSN CME Comm, Hong Kong, Peoples R China

[35] Johns Hopkins Univ, Div Cardiol, Med, Baltimore, MD USA

[36] Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA

[37] Johns Hopkins Ciccarone Ctr Prevent Cardiovasc Di, Womens Cardiovasc Hlth, Baltimore, MD USA

[38] Johns Hopkins Ciccarone Ctr Prevent Cardiovasc Di, Prevent Cardiol, Baltimore, MD USA

[39] Board Directors Amer Soc Prevent Cardiol ASPC, Baltimore, MD USA

[40] Amer Coll Cardiol ACC Prevent Leadership Council, Washington, DC USA

[41] ACCs Clin Qual Approval Comm CPAC, Washington, DC USA

[42] AHA Funding Comm, Washington, DC USA

[43] Natl Inst Hlth Funded Multiethn Study Atheroscler, Bethesda, MD USA

[44] Baylor Coll Med, Nephrol Sect, Clin Res, Houston, TX 77030 USA

[45] Baylor Coll Med, Inst Clin & Translat Res, Houston, TX 77030 USA

[46] NKF, New York, NY USA

[47] ASN, New York, NY USA

[48] OAUTHC, Dept Pediat, Pediat Nephrol & Hypertens Unit, Osun, Nigeria

[49] Obafemi Awolowo Univ, Dept Pediat & Child Hlth, Pediat Nephrol, Ife, Nigeria

[50] Univ Washington, Res Finance & Operat, Seattle, WA 98195 USA

来源：

KIDNEY INTERNATIONAL | 2022年 / 102卷 / 05期

关键词：

angiotensin-converting enzyme inhibitor; angiotensin II receptor blocker; chronic kidney disease; dialysis; evidence-based; GLP-1 receptor agonist; glycemia; glycemic monitoring; glycemic targets; guideline; HbAlc; hemodialysis; KDIGO; lifestyle; metformin; models of care; nutrition; renin-angiotensin system; self-management; SGLT2; inhibitor; systematic review; teambased care; CONVERTING-ENZYME-INHIBITION; DIETARY-PROTEIN RESTRICTION; GLUCOSE COTRANSPORTER 2; GLOMERULAR-FILTRATION-RATE; INTENSIFIED MULTIFACTORIAL INTERVENTION; ESTABLISHED CARDIOVASCULAR-DISEASE; INSULIN-DEPENDENT DIABETICS; MODERATE SODIUM RESTRICTION; ASSESSING GLYCEMIC CONTROL; URINARY ALBUMIN EXCRETION;

D O I：

10.1016/j.kint.2022.06.008

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) represents a focused update of the KDIGO 2020 guideline on the topic. The guideline targets a broad audience of clinicians treating diabetes and CKD. Topic areas for which recommendations are updated include: Chapter 1: Comprehensive care in patients with diabetes and CKD and Chapter 4: Glucose-lowering therapies in patients with type 2 diabetes (T2D) and CKD. Previous chapters on Glycemic monitoring and targets in patients with diabetes and CKD (Chapter 2), Lifestyle interventions in patients with diabetes and CKD (Chapter 3), and Approaches to management of patients with diabetes and CKD (Chapter 5) have been deemed current and their content has remained unchanged. Development of this guideline update followed an explicit process of evidence review and appraisal. Treatment approaches and guideline recommendations are based on systematic reviews of relevant studies, and appraisal of the quality of the evidence and the strength of recommendations followed the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) approach. Limitations of the evidence are discussed and areas of future research are also presented.

引用

页码：S1 / S127

页数：127

共 50 条

[21] Commentary on the 2021 update of the KDIGO clinical practice guideline for management of blood pressure in chronic kidney disease
See, Emily J.
Cullen, Vanessa
NEPHROLOGY, 2025, 30 (01)
[22] Recommendations for European laboratories based on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
Cavalier, Etienne
Zima, Tomas
Datta, Pradip
Makris, Konstantinos
Schaeffner, Elke
Langlois, Michel
Plebani, Mario
Delanaye, Pierre
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2025, 63 (03) : 525 - 534
[23] Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease
Martin, Paul
Awan, Ahmed A.
Berenguer, Marina C.
Bruchfeld, Annette
Fabrizi, Fabrizio
Goldberg, David S.
Jia, Jidong
Kamar, Nassim
Mohamed, Rosmawati
Pessoa, Mario Guimaraes
Pol, Stanislas
Sise, Meghan E.
Balk, Ethan M.
Gordon, Craig E.
Adam, Gaelen
Cheung, Michael
Earley, Amy
Jadoul, Michel
KIDNEY INTERNATIONAL, 2022, 102 (06) : 1228 - 1237
[24] Management of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice Guideline
Tomson, Charles R., V
Cheung, Alfred K.
Mann, Johannes F. E.
Chang, Tara, I
Cushman, William C.
Furth, Susan L.
Hou, Fan Fan
Knoll, Gregory A.
Muntner, Paul
Pecoits-Filho, Roberto
Tobe, Sheldon W.
Lytvyn, Lyubov
Craig, Jonathan C.
Tunnicliffe, David J.
Howell, Martin
Tonelli, Marcello
Cheung, Michael
Earley, Amy
Ix, Joachim H.
Sarnak, Mark J.
ANNALS OF INTERNAL MEDICINE, 2021, 174 (09) : 1270 - +
[25] KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know
Awdishu, Linda
Maxson, Rebecca
Gratt, Chelsea
Rubenzik, Tamara
Battistella, Marisa
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2025,
[26] KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease Hypertension News-Screen
Prischl, F.
JOURNAL FUR HYPERTONIE, 2021, 25 (01): : 21 - +
[27] 2022 Clinical Practice Guideline Update for Diabetes Management of Chronic Kidney Disease: An Important First Step, More Work to Do
Saunders, Milda
Laiteerapong, Neda
ANNALS OF INTERNAL MEDICINE, 2023, 176 (03) : 417 - 418
[28] A short clinical practice guideline proposal for the chronic kidney disease management
Ramos, Jorge Felix Rodriguez
Miranda, Guillermo Luis Herrera
MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2023, 21 (01): : 248 - 260
[29] Summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation
Chadban, Steven J.
Ahn, Curie
Axelrod, David A.
Foster, Bethany J.
Kasiske, Bertram L.
Kher, Vijah
Kumar, Deepali
Oberbauer, Rainer
Pascual, Julio
Pilmore, Helen L.
Rodrigue, James R.
Segev, Dorry L.
Sheerin, Neil S.
Tinckam, Kathryn J.
Wong, Germaine
Balk, Ethan M.
Gordon, Craig E.
Earley, Amy
Rofeberg, Valerie
Knoll, Gregory A.
TRANSPLANTATION, 2020, 104 (04) : 708 - 714
[30] KDIGO 2018 CLINICAL PRACTICE GUIDELINE FOR THE PREVENTION, DIAGNOSIS, EVALUATION, AND TREATMENT OF HEPATITIS C IN CHRONIC KIDNEY DISEASE
Wheeler, David C.
Winkelmayer, Wolfgang C.
KIDNEY INTERNATIONAL SUPPLEMENTS, 2018, 8 (03) : 91 - 165

← 1 2 3 4 5 →